Skip to main content

Table 3 Responses to survey questions regarding willingness to participate in clinical trials including various treatments and procedures

From: Attitudes toward clinical trials across the Alzheimer’s disease spectrum

Trial design elements

Diagnostic group

Likelihood of participation

Very unlikely (score = 1–2)

Neutral (score = 3–5)

Very likely (score = 6–7)

Approved

CN

6 (16.2%)

19 (51.4%)

12 (32.4%)

MCI

2 (6.25%)

12 (37.5%)

18 (56.3%)

Dementia

0 (0.00%)

5 (22.7%)

17 (77.3%)

Experimental

CN

11 (29.7%)

21 (56.8%)

5 (13.5%)

MCI

4 (12.5%)

17 (53.1%)

11 (34.4%)

Dementia

5 (22.7%)

4 (18.2%)

13 (59.1%)

Pill

CN

7 (18.9%)

21 (56.8%)

9 (24.3%)

MCI

4 (12.5%)

14 (43.8%)

14 (43.8%)

Dementia

4 (18.2%)

3 (13.6%)

15 (68.2%)

Infused

CN

12 (32.4%)

23 (62.2%)

2 (5.4%)

MCI

9 (28.1%)

17 (53.1%)

6 (18.8%)

Dementia

6 (27.3%)

9 (40.9%)

7 (31.8%)

Diet/exercise

CN

4 (10.8%)

18 (48.65%)

15 (40.5%)

MCI

4 (12.5%)

10 (31.3%)

18 (56.3%)

Dementia

3 (13.6%)

8 (36.4%)

11 (50.0%)

Supplement

CN

4 (10.8%)

13 (35.1%)

20 (54.1%)

MCI

2 (6.3%)

9 (28.1%)

21 (65.6%)

Dementia

2 (9.1%)

8 (36.4%)

12 (54.6%)

MRI

CN

7 (18.9%)

12 (32.4%)

18 (48.7%)

MCI

7 (21.9%)

8 (25.0%)

17 (53.1%)

Dementia

4 (18.2%)

9 (40.9%)

9 (40.9%)

PET scan

CN

12 (32.4%)

11 (29.7%)

14 (37.8%)

MCI

8 (25.0%)

9 (28.1%)

15 (46.8%)

 

Dementia

4 (18.2%)

9 (40.9%)

9 (40.9%)

Lumbar

CN

24 (64.8%)

12 (32.4%)

1 (2.7%)

punctures

MCI

15 (46.9%)

9 (28.1%)

8 (25.0%)

 

Dementia

10 (45.4%)

9 (40.9%)

3 (13.6%)

Bleeding in brain or gut

CN

30 (81.1%)

6 (16.2%)

1 (2.7%)

MCI

18 (56.3%)

11 (34.4%)

3 (9.4%)

Dementia

10 (45.5%)

9 (40.9%)

3 (13.6%)

Headache or nausea

CN

15 (40.5%)

20 (54.1%)

2 (5.4%)

MCI

9 (28.1%)

16 (50.0%)

7 (21.9%)

Dementia

9 (40.9%)

8 (36.4%)

5 (22.7%)

  1. Values are shown as n (%)
  2. CN cognitively normal, MCI mild cognitive impairment, MRI magnetic resonance imaging, PET positron emission tomography